NUAK1-Dependent Tau Ser356 Phosphorylation in Alzheimer’s Di
2026-04-15
This study elucidates the role of NUAK1-driven phosphorylation of tau at Ser356 in Alzheimer’s disease (AD) progression. It demonstrates that pharmacological inhibition using WZ4003 specifically reduces pathogenic p-tau Ser356 in human brain cultures, providing mechanistic insight for future therapeutic strategies.
Cy5 Goat Anti-Mouse IgG (H+L) Antibody in High-Sensitivity D
2026-04-14
The Cy5 Goat Anti-Mouse IgG (H+L) Antibody enables robust, multiplexable, and ultra-sensitive detection of mouse IgG in advanced immunoassays. Leveraging Cy5 fluorescence and affinity purification, this APExBIO reagent is optimized for translational workflows, from immunocytochemistry to cutting-edge hybrid vaccine studies.
Applied Protocols with Angiotensin I for Cardiovascular Rese
2026-04-13
Leverage Angiotensin I (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) for precision cardiovascular and neuroendocrine workflows. This guide details advanced experimental protocols, optimization strategies, and troubleshooting tips—grounded in recent research and APExBIO’s rigorously characterized peptide—for maximized reproducibility and assay performance.
TAI-1: Precision Hec1 Inhibitor Workflows for Cancer Researc
2026-04-12
TAI-1, a first-in-class Hec1 inhibitor, offers exceptionally potent and selective disruption of mitotic regulation, making it a transformative tool for oncology research. This guide details advanced workflows, troubleshooting strategies, and practical insights—empowering researchers to maximize TAI-1’s impact in cancer cell models.
Mubritinib (TAK 165): Optimizing Complex I Inhibition Workfl
2026-04-12
Mubritinib (TAK 165) is redefining how researchers target mitochondrial complex I inhibition in drug-resistant cancers and select viral models. This article delivers actionable workflows, protocol enhancements, and troubleshooting strategies that leverage Mubritinib’s selectivity and robust in vitro/in vivo performance, with insights drawn from recent antiviral screening breakthroughs.
Simvastatin (Zocor): Applied Workflows and Assay Optimizatio
2026-04-11
Simvastatin (Zocor) from APExBIO empowers researchers to probe cholesterol metabolism and apoptosis induction in hepatic cancer cells with reproducible, high-content results. This article integrates evidence-based workflows, troubleshooting advice, and machine learning–driven phenotypic profiling to maximize experimental success in cardiovascular and cancer biology.
EPZ5676: Optimizing DOT1L Inhibitor Workflows for Leukemia R
2026-04-11
EPZ5676, a potent and selective DOT1L inhibitor, empowers researchers to dissect MLL-rearranged leukemia and histone methylation pathways with unprecedented precision. This guide details optimized experimental workflows, troubleshooting strategies, and actionable insights, drawing on cutting-edge studies and comparative resources.
Mubritinib (TAK 165): Scenario-Driven Solutions for AML a...
2026-04-10
This article presents real-world laboratory scenarios where Mubritinib (TAK 165, SKU B1543) delivers reproducible, data-backed solutions for oxidative phosphorylation inhibition, apoptosis induction, and selective cytotoxicity in chemotherapy-resistant acute myeloid leukemia (AML) and primary effusion lymphoma (PEL) assays. Learn how APExBIO’s Mubritinib B1543 provides workflow reliability, protocol flexibility, and vendor assurance for advanced cancer and viral oncology research.
Mubritinib (TAK 165): Optimizing Mitochondrial Inhibition...
2026-04-09
This article provides a scenario-driven, evidence-based guide for leveraging Mubritinib (TAK 165) (SKU B1543) in cell-based viability and cytotoxicity assays, with a focus on acute myeloid leukemia (AML) and primary effusion lymphoma (PEL) research. Using real-world laboratory questions, we delineate how Mubritinib’s unique profile as a selective mitochondrial complex I inhibitor supports robust, reproducible, and interpretable experimental outcomes.
Mubritinib (TAK 165): From HER2 Inhibition to Precision M...
2026-04-08
Explore Mubritinib (TAK 165), a selective HER2/ErbB2 inhibitor repurposed as a mitochondrial electron transport chain complex I inhibitor, and its transformative role in targeted cancer therapy research. This in-depth article reveals advanced mechanisms, assay strategies, and applications in chemotherapy-resistant AML and primary effusion lymphoma, offering a unique systems-level perspective for translational scientists.
Mubritinib (TAK 165): Beyond HER2—A Next-Gen Mitochondria...
2026-04-08
Discover the multifaceted role of Mubritinib (TAK 165) as a mitochondrial electron transport chain complex I inhibitor—far surpassing its origins as a HER2 inhibitor. This article uniquely explores its cutting-edge applications in chemotherapy-resistant AML, primary effusion lymphoma, and KSHV-driven cancer research.
Mubritinib (TAK 165): Mechanistic Insight and Strategic G...
2026-04-07
This thought-leadership article redefines the translational potential of Mubritinib (TAK 165), a next-generation mitochondrial electron transport chain complex I inhibitor, for acute myeloid leukemia (AML), primary effusion lymphoma (PEL), and KSHV-driven oncogenesis. Bridging mechanistic underpinnings, workflow strategies, and future-facing clinical guidance, we synthesize evidence from landmark studies and best-in-class resources, offering translational scientists a framework for deploying Mubritinib (TAK 165) from APExBIO as a cornerstone of innovative cancer and viral research.
Mubritinib (TAK 165): Precision Inhibition of Mitochondri...
2026-04-07
Mubritinib (TAK 165) is a selective inhibitor of mitochondrial electron transport chain complex I, showing potent, OXPHOS-dependent cytotoxicity in acute myeloid leukemia (AML) and primary effusion lymphoma (PEL) models. Its mechanism and specificity make it a leading tool compound for dissecting chemotherapy resistance and mitochondrial metabolism in advanced cancer biology.
Optimizing Angiogenesis and Fibrosis Assays with SAR13167...
2026-04-06
This article provides a scenario-driven, evidence-based guide for leveraging SAR131675, a selective and ATP-competitive VEGFR-3 inhibitor (SKU B2301), in cell viability, proliferation, and cytotoxicity research. Drawing on recent literature, validated assay data, and practical laboratory scenarios, it demonstrates how precise targeting of VEGFR-3 enhances reliability and interpretation in angiogenesis and lymphangiogenesis studies. Researchers will find actionable insights on optimizing workflows, minimizing off-target effects, and selecting the most robust inhibitor for preclinical experimentation.
Optimizing Cell Assays with SAR131675, a Selective ATP-Co...
2026-04-06
This article delivers scenario-driven, evidence-based guidance for using SAR131675, a selective and ATP-competitive VEGFR-3 inhibitor (SKU B2301), in cell viability, proliferation, and cytotoxicity assays. It addresses real laboratory challenges, provides quantitative context, and highlights how SAR131675’s selectivity and validated performance support reproducible results in cancer and hepatic fibrosis research workflows.
461 records 22/31 page Previous Next First page 上5页 2122232425 下5页 Last page